This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Law, L. W. Articles by Hearing, V. J. Search for Related Content PubMed PubMed Citation Articles by Law, L. W. Articles by Hearing, V. J.

A Unique Tumor Rejection Antigen from the S91 Murine Malignant Melanoma

Laboratory of Cell Biology, National Cancer Institute, Bethesda, Maryland 20892

We have identified and described the characteristics of a unique tumor rejection antigen (tumor-specific transplantation antigen) obtained from the murine malignant melanoma S91. This antigen is highly restricted to the autologous melanoma and provides striking inhibition of its growth. Previously, we described common or shared tumor-specific transplantation antigens on the murine malignant melanomas B16 F10, K1735, JB/RH, and JB/MS. No cross-reactivity was obtained in this study between S91 and those four other malignant melanomas. The common tumor-specific transplantation antigen resides on a glycoprotein molecule with a molecular weight of 65,000, termed B700, that shares homology with serum albumin as determined by NH₂-terminal amino acid sequencing. B700, however, purified from S91 proved to be ineffective as an immunogen.

¹ To whom requests for reprints should be addressed, at the National Cancer Institute, Bldg. 37, Rm. 1B22, Bethesda, MD 20892.

Received 5/18/87. Revised 8/11/87. Accepted 8/17/87.